960401-42-7

Usage

Uses

Used in Pharmaceutical Industry:
Tert-butyl 3-(4-amino-2-methoxyphenoxy)azetidine-1-carboxylate is used as a building block for the synthesis of various drugs and pharmaceutical compounds. Its unique structure and properties make it suitable for use in drug development, particularly in the creation of new treatments for various medical conditions.
Used in Chemical Research and Development:
This chemical may also have potential applications in the field of chemical research and development for other purposes, such as in materials science and organic synthesis. Its unique properties and structure can contribute to the advancement of scientific knowledge and the development of new materials and compounds.

Upstream product

• 960401-34-7 3-(2-methoxy-4-nitro-phenoxy)-azetidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 960401-64-3 3-(4-{[5-(4-chloro-phenyl)-3-(2-hydroxy-ethyl)-thiophene-2-carbonyl]-amino}-2-methoxy-phenoxy)-azetidine-1-carboxylic acid tert-butyl ester 
• 1035219-49-8 3-(4-{[2-(4-chlorophenyl)-4-(2-hydroxyethyl)thiazole-5-carbonyl]amino}-2-methoxyphenoxy)azetidine-1-carboxylic acid tert-butyl ester 
• 1035219-72-7 3-(4-{[2-(4-chlorophenyl)-4-methoxycarbonylmethylthiazole-5-carbonyl]amino}-2-methoxyphenoxy)azetidine-1-carboxylic acid tert-butyl ester 
• 1035219-47-6 3-(4-{[2-(4-chlorophenyl)-4-(2,2-dimethoxyethyl)thiazole-5-carbonyl]amino}-2-methoxyphenoxy)azetidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

5- [4- (AZETIDIN-3-YL0XY) -PHENYL] -2-PHENYL-5H-THIAZ0L0 [5,4-C] PYRIDIN-4-0NE DERIVATIVES AND THEIR USE AS MCH RECEPTOR ANTAGONISTS

The present invention relates to a melanin concentrating hormone antagonist compound of formula I: wherein "-----" is absent or is optionally a bond; q is 1 or 2; R1 is independently selected from hydrogen, -C1-C2 alkyl, halo, hydroxy, -C1-C2 haloalkyl, -C1-C3 alkoxy, cyano, -O-C3-C4 cycloalkyl, and -OC1-C2 haloalkyl; R2 is selected from the group consisting of hydrogen, -C1-C3 alkyl, hydroxy, -C1-C3 alkoxy, cyano, -C1-C2 haloalkyl, -OC1-C2 haloalkyl, and halo; R3 is selected from the group consisting of hydrogen, -C1-C4 alkyl, -C2-C4 haloalkyl, -C2-C4 alkylOH, -C3-C6 cycloalkyl, -CH2C3-C6 cyxloalkyl, -C2-C4 alkyl-O-C1-C4 alkyl, -C(O)C1-C4 alkyl, -C(O)C1-C4 haloalkyl, -CH2-thiazole, phenyl, benzyl, tetrahydrothiopyranyl, and tetrahydropyranyl, wherein the cycloalkyl, tetrahydrothiopyranyl, tetrahydropyranyl and thiazolyl group is optionally substituted with one or two groups independently selected from the group consisting of halo, hydroxy, C1-C2 alkyl, and -C1-C2 haloalkyl; or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof,, useful in the treating, preventing or ameliorating of symptoms associated with obesity and related diseases.

NOVEL MCH RECEPTOR ANTAGONISTS

The present invention relates to a melanin concentrating hormone antagonist compound of formula (I): wherein R1, Ra, Rb, R2, L1, R3, R4 and R5 are as defined, or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture of diasteromers thereof useful in the treatment, obesity and related diseases.